SMAD3 and inflammatory bowel disease: Further studies will be needed to determine precise mechanisms by which WIN 18,446-mediated reduction of RA alleviates IBD in Smad3−/−, including the role of α4β7 integrin and other integrins affected by RA reduction as well as other processes that may be changed due to RA reduction.